In summary, the present work supports further optimization of the small-molecule Stat5 inhibitor IST5 for oral bioavailability to enable clinical development of IST5 for therapies for solid tumors, hematological malignancies and myeloproliferative disorders. Here, STAT5B is linked to myeloproliferative disorder.